Entrada Therapeutics, Inc. TRDA
We take great care to ensure that the data presented and summarized in this overview for Entrada Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TRDA
View all-
Baker Bros. Advisors LP New York, NY4.87MShares$73.6 Million0.87% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$67 Million25.58% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$66.7 Million22.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.75MShares$41.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.49MShares$22.5 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA1.28MShares$19.4 Million0.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.08MShares$16.3 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA1.03MShares$15.5 Million0.0% of portfolio
-
Step Stone Group LP La Jolla, CA761KShares$11.5 Million2.57% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA585KShares$8.85 Million0.87% of portfolio
Latest Institutional Activity in TRDA
Top Purchases
Top Sells
About TRDA
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Insider Transactions at TRDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2024
|
Natarajan Sethuraman Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,675
-4.84%
|
$145,125
$15.19 P/Share
|
|
May 17
2024
|
Natarajan Sethuraman Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,305
-3.99%
|
$124,575
$15.14 P/Share
|
|
May 17
2024
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,200
-0.35%
|
$18,000
$15.11 P/Share
|
|
May 16
2024
|
Natarajan Sethuraman Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,000
-0.48%
|
$15,000
$15.0 P/Share
|
|
May 16
2024
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,800
-0.53%
|
$27,000
$15.0 P/Share
|
|
May 14
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
25,000
+21.29%
|
$350,000
$14.59 P/Share
|
|
May 09
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
2,200
+3.16%
|
$30,800
$14.25 P/Share
|
|
May 08
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
2,276
+3.37%
|
$31,864
$14.04 P/Share
|
|
Apr 08
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
2,600
+3.97%
|
$33,800
$13.57 P/Share
|
|
Mar 28
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
1,512
+2.44%
|
$19,656
$13.75 P/Share
|
|
Mar 26
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
2,750
+4.47%
|
$35,750
$13.64 P/Share
|
|
Mar 25
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
3,180
+5.37%
|
$41,340
$13.36 P/Share
|
|
Mar 22
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
3,118
+5.57%
|
$40,534
$13.76 P/Share
|
|
Mar 21
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
704
+1.39%
|
$9,152
$13.24 P/Share
|
|
Mar 20
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
1,128
+2.25%
|
$13,536
$12.66 P/Share
|
|
Mar 19
2024
|
Peter S Kim Director |
BUY
Open market or private purchase
|
Direct |
900
+1.84%
|
$10,800
$12.66 P/Share
|
|
Mar 15
2024
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+9.76%
|
$18,000
$2.1 P/Share
|
|
Mar 06
2024
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,086
-5.22%
|
$49,032
$12.31 P/Share
|
|
Mar 06
2024
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
1,826
-1.31%
|
$21,912
$12.32 P/Share
|
|
Mar 05
2024
|
Natarajan Sethuraman Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,505
-0.71%
|
$18,060
$12.28 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 379K shares |
|---|---|
| Exercise of conversion of derivative security | 84.5K shares |
| Open market or private purchase | 45.4K shares |
| Payment of exercise price or tax liability | 17.5K shares |
|---|---|
| Open market or private sale | 145K shares |